CVS' Health Services segment posts $43B in revenues as specialty pharmacy and Caremark deals drive 2025 growth prospects.

CVS Caremark identified GLP-1 drugs and Humira as points of contention, but the State Health Plan says that mischaracterizes ...

Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Health insurance plans are changing how they cover GLP-1 drugs for weight loss to rein in costs, forcing doctors and patients ...

Starting July 1, Caremark will list Novo Nordisk’s NVO Wegovy as the preferred GLP-1 medicine on its largest commercial template formularies. The Novo Nordisk partnership echoes CVS’ launch of ...

CVS Caremark is the plan’s pharmacy benefit manager ... the manufacturer of GLP-1s Wegovy and Saxenda. That saved the state $539 off the $1,347 list price for each prescription of both drugs ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Earlier this month, Novo announced that CVS Caremark chose Wegovy to be its preferred GLP-1 medication for obesity and weight-loss. 2 This policy will go into effect at the start of July. In a press ...

The healthcare sector is dominated by massive players, but few are as influential as UnitedHealth Group Incorporated UNH and ...